Literature DB >> 29061464

The eighth edition TNM stage classification for lung cancer: What does it mean on main street?

Frank C Detterbeck1.   

Abstract

Entities:  

Mesh：

Year:  2017        PMID： 29061464     DOI： 10.1016/j.jtcvs.2017.08.138

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN： 0022-5223            Impact factor:   5.209


× No keyword cloud information.
  35 in total

1.  Prognostic Impact of PCK1 Protein Kinase Activity-Dependent Nuclear SREBP1 Activation in Non-Small-Cell Lung Carcinoma.

Authors:  Fei Shao; Xueli Bian; Juhong Wang; Daqian Xu; Wei Guo; Hongfei Jiang; Gaoxiang Zhao; Lei Zhu; Shuai Wang; Dongming Xing; Yibo Gao; Jie He; Zhimin Lu
Journal:  Front Oncol       Date:  2021-03-26       Impact factor: 6.244

Review 2.  Preoperative and Postoperative Systemic Therapy for Operable Non-Small-Cell Lung Cancer.

Authors:  Jamie E Chaft; Yu Shyr; Boris Sepesi; Patrick M Forde
Journal:  J Clin Oncol       Date:  2022-01-05       Impact factor: 44.544

3.  Silencing EGFR-upregulated expression of CD55 and CD59 activates the complement system and sensitizes lung cancer to checkpoint blockade.

Authors:  Fei Shao; Yibo Gao; Wei Wang; Haiyan He; Liwei Xiao; Xiao Geng; Yan Xia; Dong Guo; Jing Fang; Jie He; Zhimin Lu
Journal:  Nat Cancer       Date:  2022-10-21

4.  Disparities in clinical and demographic characteristics among Asian/Pacific Islander and Non-Hispanic White newly diagnosed lung cancer patients.

Authors:  Parth B Patel; Naomi Alpert; Emanuela Taioli; Raja Flores
Journal:  Cancer Causes Control       Date:  2022-01-19       Impact factor: 2.506

5.  Early circulating tumour DNA kinetics measured by ultra-deep next-generation sequencing during radical radiotherapy for non-small cell lung cancer: a feasibility study.

Authors:  G M Walls; L McConnell; J McAleese; P Murray; T B Lynch; K Savage; G G Hanna; D Gonzalez de Castro
Journal:  Radiat Oncol       Date:  2020-05-29       Impact factor: 3.481

6.  Systemic immune-inflammation index (SII) is useful to predict survival outcomes in patients with surgically resected non-small cell lung cancer.

Authors:  Wei Guo; Songhua Cai; Fan Zhang; Fei Shao; Guochao Zhang; Yang Zhou; Liang Zhao; Fengwei Tan; Shugeng Gao; Jie He
Journal:  Thorac Cancer       Date:  2019-02-07       Impact factor: 3.500

7.  Determination of prognostic factors of surgically treated pathological Stage IIIA non-small cell lung cancer.

Authors:  Muhammet Sayan; Elgun Valiyev; Merve Satır Türk; Aynur Baş; Ali Çelik; İsmail Cüneyt Kurul; Olgun Kadir Arıbaş; Abdullah İrfan Taştepe
Journal:  Turk Gogus Kalp Damar Cerrahisi Derg       Date:  2020-07-28       Impact factor: 0.332

Review 8.  Durvalumab: a potential maintenance therapy in surgery-ineligible non-small-cell lung cancer.

Authors:  Michael R Shafique; Lary A Robinson; Scott Antonia
Journal:  Cancer Manag Res       Date:  2018-05-01       Impact factor: 3.989

Review 9.  Spontaneous regression of ALK fusion protein-positive non-small cell lung carcinoma: a case report and review of the literature.

Authors:  Maria Walls; Gerard M Walls; Jacqueline A James; Kyle T Crawford; Hossam Abdulkhalek; Tom B Lynch; Aaron J Peace; Terry E McManus; O Rhun Evans
Journal:  BMC Pulm Med       Date:  2020-08-06       Impact factor: 3.317

Review 10.  CXCR4 Based Therapeutics for Non-Small Cell Lung Cancer (NSCLC).

Authors:  Ori Wald
Journal:  J Clin Med       Date:  2018-09-25       Impact factor: 4.241
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.